Volume 382, Issue 9903, Pages (November 2013)

Slides:



Advertisements
Similar presentations
Crohn's disease Prof Daniel C Baumgart, MD, Prof William J Sandborn, MD The Lancet Volume 380, Issue 9853, Pages (November 2012) DOI: /S (12)
Advertisements

Volume 366, Issue 9481, Pages (July 2005)
Volume 370, Issue 9586, Pages (August 2007)
Allergic diseases and the effect of inhaled epinephrine in children with acute bronchiolitis: follow-up from the randomised, controlled, double-blind,
Volume 380, Issue 9846, Pages (September 2012)
Volume 364, Issue 9440, Pages (September 2004)
Volume 16, Issue 2, Pages (February 2015)
Volume 367, Issue 9517, Pages (April 2006)
Volume 378, Issue 9788, Pages (July 2011)
Volume 357, Issue 9257, Pages (March 2001)
Volume 370, Issue 9601, Pages (November 2007)
Volume 12, Issue 11, Pages (October 2011)
Volume 376, Issue 9747, Pages (October 2010)
Point-of-care C-reactive protein testing to reduce inappropriate use of antibiotics for non-severe acute respiratory infections in Vietnamese primary.
Volume 11, Issue 4, Pages (April 2012)
Volume 388, Issue 10058, Pages (November 2016)
Volume 15, Issue 6, Pages (May 2014)
Bipolar treatment efficacy
Volume 386, Issue 10008, Pages (November 2015)
Meta-analysis of randomised controlled trials
Volume 5, Issue 4, Pages (April 2006)
Volume 377, Issue 9779, Pages (May 2011)
Point-of-care C-reactive protein testing to reduce inappropriate use of antibiotics for non-severe acute respiratory infections in Vietnamese primary.
Volume 389, Issue 10076, Pages (April 2017)
Andrea Ganna, PhD, Prof Erik Ingelsson, MD  The Lancet 
Volume 12, Issue 9, Pages (September 2013)
Volume 14, Issue 12, Pages (December 2015)
Volume 374, Issue 9707, Pages (December 2009)
Volume 356, Issue 9241, Pages (November 2000)
Volume 373, Issue 9663, Pages (February 2009)
Volume 382, Issue 9903, Pages (November 2013)
An integrated clinicoradiological staging system for pulmonary sarcoidosis: a case- cohort study  Dr Simon LF Walsh, MD, Prof Athol U Wells, MD, Nicola.
Volume 389, Issue 10077, Pages (April 2017)
Volume 12, Issue 7, Pages (July 2011)
Incident diabetes in clinical trials of antihypertensive drugs
Prediction of ESRD and Death Among People With CKD: The Chronic Renal Impairment in Birmingham (CRIB) Prospective Cohort Study  Martin J. Landray, PhD,
Volume 379, Issue 9812, Pages (January 2012)
Volume 15, Issue 1, Pages (January 2014)
Lung cancer diagnosis and staging with endobronchial ultrasound-guided transbronchial needle aspiration compared with conventional approaches: an open-label,
Volume 20, Issue 1, Pages (January 2019)
Volume 14, Issue 11, Pages (October 2013)
Volume 381, Issue 9868, Pages (March 2013)
Volume 18, Issue 3, Pages (March 2017)
Volume 386, Issue 10008, Pages (November 2015)
Volume 375, Issue 9709, Pages (January 2010)
Volume 372, Issue 9647, Pages (October 2008)
Volume 388, Issue 10058, Pages (November 2016)
Volume 371, Issue 9627, Pages (May 2008)
Volume 378, Issue 9786, Pages (July 2011)
Volume 376, Issue 9757, Pages (December 2010)
Volume 9, Issue 4, Pages (April 2008)
Volume 15, Issue 6, Pages (May 2014)
Volume 5, Issue 4, Pages (April 2018)
Volume 375, Issue 9726, Pages (May 2010)
Volume 375, Issue 9719, Pages (March 2010)
Volume 15, Issue 6, Pages (May 2014)
Volume 15, Issue 1, Pages (January 2014)
Volume 361, Issue 9352, Pages (January 2003)
Volume 62, Issue 1, Pages (July 2002)
Volume 11, Issue 3, Pages (March 2010)
Volume 371, Issue 9618, Pages (March 2008)
Volume 389, Issue 10068, Pages (February 2017)
Volume 375, Issue 9715, Pages (February 2010)
Volume 376, Issue 9747, Pages (October 2010)
Volume 13, Issue 7, Pages (July 2014)
Volume 368, Issue 9541, Pages (September 2006)
Volume 385, Issue 9985, Pages (June 2015)
Interferon alfa-2a for melanoma metastases
Volume 14, Issue 7, Pages (June 2013)
Efficacy of live oral rotavirus vaccines by duration of follow-up: a meta-regression of randomised controlled trials  Andrew Clark, PhD, Kevin van Zandvoort,
Presentation transcript:

Volume 382, Issue 9903, Pages 1496-1506 (November 2013) Percutaneous vesicoamniotic shunting versus conservative management for fetal lower urinary tract obstruction (PLUTO): a randomised trial  Rachel K Morris, PhD, Gemma L Malin, MD, Elisabeth Quinlan-Jones, MSc, Lee J Middleton, MSc, Karla Hemming, PhD, Danielle Burke, MSc, Jane P Daniels, PhD, Prof Khalid S Khan, MSc, Prof Jon Deeks, PhD, Prof Mark D Kilby, DSc  The Lancet  Volume 382, Issue 9903, Pages 1496-1506 (November 2013) DOI: 10.1016/S0140-6736(13)60992-7 Copyright © 2013 Elsevier Ltd Terms and Conditions

Figure 1 Trial profile Normal renal function is defined as serum creatinine less than 50 μmol/L; mild renal impairment is defined as serum creatinine of 50 μmol/L or more, not requiring medical treatment; moderate renal impairment is defined as serum creatinine of 50 μmol/L or more, requiring medical treatment; end-stage renal failure is defined as need for transplant or dialysis. TOP=termination of pregnancy. *Two treatment related TOPs occurred secondary to spontaneous rupture of membranes after shunt insertion at 17 and 22 weeks. † Parental decision at 18–25 weeks. ‡After spontaneous rupture of membranes at 16 weeks. §Due to pulmonary hypoplasia. The Lancet 2013 382, 1496-1506DOI: (10.1016/S0140-6736(13)60992-7) Copyright © 2013 Elsevier Ltd Terms and Conditions

Figure 2 Results of Bayesian analysis Bayesian prior and posterior estimates of relative risk of survival to age 28 days. The prior distribution (A) was obtained by eliciting prior distributions from 52 experts, averaging the distributions, and fitting a normal distribution. The posterior distribution (B) is based on combining the elicited prior with the intention-to-treat results. The posterior distribution (C) is based on combining a non-informative prior with the intention-to-treat results. The Lancet 2013 382, 1496-1506DOI: (10.1016/S0140-6736(13)60992-7) Copyright © 2013 Elsevier Ltd Terms and Conditions

Figure 3 Kaplan-Meier estimates of survival from conception to end of follow-up Vertical dashes on the lines represent censored observations, either through parental choice to terminate pregnancy (before 36·5 weeks) or end of follow-up. Hazard ratios (HRs) were calculated for the period 0–36·5 weeks and from 36·5 weeks to the end of follow-up (conditional on survival to 36·5 weeks). These HRs are Bayesian estimates based on non-informative priors. The hazard rate comparison is of conservative management versus vesicoamniotic shunt, such that the interpretation of HRs greater than 1 as being indicative of benefit is consistent with the interpretation of the relative risk estimates. CrI=credibility interval. The Lancet 2013 382, 1496-1506DOI: (10.1016/S0140-6736(13)60992-7) Copyright © 2013 Elsevier Ltd Terms and Conditions